Profiling of Drug-Metabolizing Enzymes and Transporters in Human Tissue Biopsy Samples: A Review of the Literature

被引:14
作者
Rodrigues, A. David [1 ]
Rowland, Andrew [2 ]
机构
[1] Pfizer Inc, ADME Sci Med Design Worldwide Res & Dev, Eastern Point Rd,Bldg 220-002-2565, Groton, CT 06340 USA
[2] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia
关键词
CYTOCHROME-P450; 3A4/5; ACTIVITY; INTESTINAL P-GLYCOPROTEIN; MESSENGER-RNA EXPRESSION; ACTIVITY IN-VIVO; HUMAN-LIVER; UDP-GLUCURONOSYLTRANSFERASE; PHARMACOKINETIC MODEL; DECREASED EXPRESSION; EFFLUX TRANSPORTERS; GENE-EXPRESSION;
D O I
10.1124/jpet.119.262972
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Within the drug pharmacokinetics (PK)-absorption, distribution, metabolism, and excretion (ADME) research community, investigators regularly generate in vitro data sets using appropriately vendor-sourced and processed human tissue. Such data enable drug screening, the generation of kinetic parameters, extrapolation of in vitro to in vivo, as well as the modeling and simulation of drug PK. Although there are large numbers of manuscripts describing studies with deceased organ donor tissue, relatively few investigators have published studies utilizing living donor tissue biopsy samples. After a review of the available literature, it was possible to find publications describing the use of tissue biopsy samples to determine enzyme inhibition ex vivo, the study of genotype-phenotype associations, the evaluation of tissue expression profiling following an inducer, and assessment of correlations between tissue expression profiles and in vivo-derived trait measures (e.g., biomarker plasma levels and probe drug PK). Some reports described multiple single-tissue biopsies, whereas others described singlemultiple-organ biopsies. It is concluded that biopsy-derived data can support modeling exercises (as input data and when validating models) and enable the assessment of organ-specific changes in enzyme and transporter profiles resulting from drug interactions, disease (e.g., metabolic disease, fibrosis, inflammation, cancer, infection), age, pregnancy, organ impairment, and genotype. With the emergence of multiorgan axes (e.g., microbiome-gut-liver-kidney) and interest in remote sensing (interorgan communication), it is envisioned that there will be increased demand for single- and multiorgan tissue biopsy data to support hypothesis testing and PK-ADME model building. SIGNIFICANCE STATEMENT Based on a review of the literature, it is apparent that profiling of human tissue biopsy samples is useful in support of pharmacokinetics (PK)-absorption, distribution, metabolism, and excretion (ADME)-related studies. With conventional tissue biopsy as precedent, it is envisioned that researchers will turn to less invasive "liquid biopsy" methods in support of ADME-related studies (e.g., profiling of plasma-derived tissue-specific nanovesicles). Generation of such multiorgan liquid biopsy data in larger numbers of subjects and at multiple study time points will provide a rich data set for modeling purposes.
引用
收藏
页码:308 / 319
页数:12
相关论文
共 87 条
[1]  
Aiba Tetsuya, 2005, Drug Metab Pharmacokinet, V20, P268, DOI 10.2133/dmpk.20.268
[2]   Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model [J].
Almond, Lisa M. ;
Mukadam, Sophie ;
Gardner, Iain ;
Okialda, Krystle ;
Wong, Susan ;
Hatley, Oliver ;
Tay, Suzanne ;
Rowland-Yeo, Karen ;
Jamei, Masoud ;
Rostami-Hodjegan, Amin ;
Kenny, Jane R. .
DRUG METABOLISM AND DISPOSITION, 2016, 44 (06) :821-832
[3]   Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction [J].
Asaumi, Ryuta ;
Menzel, Karsten ;
Lee, Wooin ;
Nunoya, Ken-Ichi ;
Imawaka, Haruo ;
Kusuhara, Hiroyuki ;
Sugiyama, Yuichi .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (11) :845-857
[4]   UGT concentrations in human rectal tissue after multidose, oral curcumin [J].
Asher, Gary N. ;
Fallon, John K. ;
Smith, Philip C. .
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2016, 4 (02)
[5]  
Bergheim Ina, 2005, BMC Clin Pharmacol, V5, P4, DOI 10.1186/1472-6904-5-4
[6]   Atorvastatin Treatment Induces Uptake and Efflux Transporters in Human Liver [J].
Bjorkhem-Bergman, Linda ;
Bergstrom, Helena ;
Johansson, Maria ;
Parini, Paolo ;
Eriksson, Mats ;
Rane, Anders ;
Ekstrom, Lena .
DRUG METABOLISM AND DISPOSITION, 2013, 41 (09) :1610-1615
[7]   Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine [J].
Brueck, Susanne ;
Bruckmueller, Henrike ;
Wegner, Danilo ;
Busch, Diana ;
Martin, Paul ;
Oswald, Stefan ;
Cascorbi, Ingolf ;
Siegmund, Werner .
MOLECULAR PHARMACEUTICS, 2019, 16 (09) :3823-3830
[8]   Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach [J].
Brussee, Janneke M. ;
Yu, Huixin ;
Krekels, Elke H. J. ;
Palic, Semra ;
Brill, Margreke J. E. ;
Barrett, Jeffrey S. ;
Rostami-Hodjegan, Amin ;
de Wildt, Saskia N. ;
Knibbe, Catherijne A. J. .
PHARMACEUTICAL RESEARCH, 2018, 35 (09)
[9]  
BUCHTHAL J, 1995, EUR J CLIN PHARMACOL, V47, P431
[10]   The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut-liver-kidney axis [J].
Bush, Kevin T. ;
Wu, Wei ;
Lun, Christina ;
Nigam, Sanjay K. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (38) :15789-15803